Recent 8-K filings for KIDS

• April 30, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  OrthoPediatrics Q1 revenue up 13% to $59.4M; lifts FY2026 guidance to $263-267M

  Revenue $59.4M (13% YoY); US +11%, International +22%; Trauma & Deformity +14%, Scoliosis +13%.

• February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  OrthoPediatrics reports record 2025 revenue $236.3M (+15% YoY); Q4 first positive free cash flow $9.8M

  Record FY2025 revenue $236.3M, up 15% from $204.7M in 2024.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  OrthoPediatrics posts record FY2025 revenue $236.1M (+15% YoY); guides FY2026 revenue $262-266M

  Q4 2025 revenue $61.3M (+16% YoY); domestic $48.4M (+13%), international $12.9M (+32%).

• October 28, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  OrthoPediatrics Q3 revenue $61.2M (+12% YoY); adjusted EBITDA up 56% to $6.2M; raises FY2025 revenue guidance

  Revenue $61.2M, +12% YoY (17% ex-7D capital); Trauma & Deformity +17%, Scoliosis +4%.

• October 9, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  OrthoPediatrics preliminary Q3 rev $61.2M (+12% YoY); cuts FY guidance to $233.5-$234.5M

  Preliminary Q3 net revenue $61.2M, up 12% YoY; domestic $48.7M (+14%), international $12.5M (+6%).

• August 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  OrthoPediatrics Q2 revenue hits record $61.1M (+16% YoY); raises FY2025 guidance

  Revenue of $61.1M (+16% YoY); domestic up 17%, international up 12%.

• May 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  OrthoPediatrics Q1 revenue $52.4M (+17% YoY); raises FY2025 guidance to $236-242M

  Total Q1 revenue $52.4M (+17% YoY); U.S. revenue $40.9M (+19%), international $11.5M (+11%).

• March 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  OrthoPediatrics reports record FY2024 revenue of $204.7M, up 38% YoY; Q4 adjusted EBITDA doubles to $3.0M

  Full year 2024 revenue $204.7M, up 38% from $148.7M in 2023; Q4 revenue $52.7M, up 40% YoY.

• January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  OrthoPediatrics reports record FY2024 revenue of $204.7M (+38% YoY), issues 2025 guidance

  Preliminary unaudited FY2024 revenue $204.7M, up 38% from $148.7M in 2023.

• November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  OrthoPediatrics Q3 record revenue $54.6M (+37% YoY); raises FY guidance to $202-204M

  Revenue $54.6M (+37% YoY); domestic up 45%, international up 12%.

• August 12, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 3.02item 9.01

  OrthoPediatrics closes $25M term loan and $50M convertible notes issuance

  $25M term loan from Braidwell LP funded on August 12, 2024.

• August 5, 2024, 7:59 PM ET debt materiality 0.75 neutral item 1.01item 2.03item 3.02item 7.01item 8.01item 9.01

  OrthoPediatrics secures up to $100M from Braidwell: $25M term loan + $25M delayed draw + $50M convertible notes

  Term loan at SOFR + 6.50% (PIK option adds 1.00%), interest-only until August 2029 maturity.

• August 5, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M

  Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.

• May 6, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  OrthoPediatrics Q1 revenue up 41% to $44.7M; raises FY 2024 guidance to $200-203M

  Total revenue $44.7M (+41% YoY); U.S. +44%, international +33%.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.42 · Most common event earnings

10 positive 1 negative 23 neutral

source · KIDS on sec.gov